HRT Financial’s Kalaris Therapeutics KLRS Stock Holding History

HRT Financial’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$67K	Buy	+11,617	New	+$103K	﹤0.01%	3415
2025 Q1	–	Sell	-1,373	Closed	-$13K	–	3592
2024 Q4	$13K	Buy	+1,373	New	+$20.8K	﹤0.01%	2257
2023 Q1	–	Sell	-2,088	Closed	-$246K	–	3326
2022 Q4	$246K	Buy	+2,088	New	+$354K	﹤0.01%	1842
2022 Q3	–	Sell	-1,893	Closed	-$169K	–	3634
2022 Q2	$169K	Buy	1,893 +1,291	+214%	+$135K	﹤0.01%	2298
2022 Q1	$93K	Buy	+602	New	+$120K	﹤0.01%	2676
2021 Q3	–	Sell	-3,486	Closed	-$1.58M	–	3862
2021 Q2	$1.58M	Buy	+3,486	New	+$1.8M	0.01%	744

Other funds holding KLRS

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

HRT Financial's KLRS Position: Q1 2026 in Review

HRT Financial opened a new position in Kalaris Therapeutics (KLRS) in Q1 2026: 11,617 shares worth $67K. The stake represents ﹤0.01% of the portfolio and ranks #3415 among its holdings. This is a return to the name: HRT Financial previously reported a position in KLRS as recently as Q4 2024.

HRT Financial first reported a position in KLRS in Q2 2021 and has held it in 6 quarters since. The position peaked at $1.58M in Q2 2021. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

HRT Financial held 11,617 shares of Kalaris Therapeutics worth $67K as of Q1 2026.
Kalaris Therapeutics was a new HRT Financial position in Q1 2026.
Kalaris Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3415 holding.
HRT Financial first reported a position in Kalaris Therapeutics in Q2 2021 and has held it in 6 quarters since.
HRT Financial's Kalaris Therapeutics position peaked at $1.58M in Q2 2021.
58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.